Team Grant : CRISM Phase II: Regional Nodes

Eligibility: 

For a Regional Node LOI to be eligible:

  1. The Nominated Principal Applicant must be an independent researcher.
  2. The Nominated Principal Applicant must be appointed at an eligible institution (see the CIHR Application Administration Guide – Part 4) within the geographic area covered by the Regional Node they are leading by the effective date of funding.
  3. The research team must include at least one Principal Applicant who self-identifies as Indigenous (First Nations, Inuit or Métis) and/or demonstrates a track record of meaningful and culturally safe involvement with Indigenous Peoples. At the Full Application stage, a one-page document describing how they meet this requirement must be submitted as an “Other” attachment (see How to Apply section).
  4. At least one project participant must be identified as responsible for directing the Methamphetamine Use Disorder Controlled Trial within that Regional Node.
  5. At least one project participant, other than the Nominated Principal Applicant, must be a Service Provider for problematic substance use, under the broad definition of a Knowledge User.
  6. At least one project participant, other than the Nominated Principal Applicant and the Service Provider, must be a Representative from one of these categories: people with lived and living experience, including caregivers, family members, advocacy groups.
  7. The research team must include a Sex and Gender Champion listed as Nominated Principal Applicant, Principal Applicant or Co-Applicant. Champions are researchers able to meaningfully integrate considerations of sex and gender throughout all aspects of the project design, methods, analysis, implementation and reporting. The Sex and Gender Champion must have successfully completed one of the sex- and gender-based analysis training modules available online through the CIHR Institute of Gender and Health and submit a Certificate of Completion (see How to Apply section, Regional Node Full Application). Please select and complete the training module most applicable to your research project. See Additional Information for further important information on the Champion role.

In addition to meeting the requirements for the LOI, for a Regional Node Full Application to be eligible:

  1. The Full Application must have the support of regional or provincial health authorities and/or Ministries of Health, and (optional) local health units. A minimum of two (2) letters of support are required (with at least one coming from regional or provincial health authorities or Ministries of Health), but no more than five (5) letters of support in total (see How to Apply section).

Note: This funding opportunity seeks a minimum of one participant per Node who self-identifies as Indigenous (First Nations, Inuit or Métis) or provide evidence of having meaningful and culturally safe involvement with Indigenous Peoples in order to:

  1. Prioritize First Nations, Inuit and Métis Peoples and communities, including Urban Indigenous communities, in leading their research agendas;
  2. Promote cultural safety of and appropriate engagements by researchers working with Indigenous Peoples in meaningful ways to ensure that respectful relations* are established;
  3. Add value to the research through the use of Indigenous culturally relevant theoretical and conceptual frameworks, and Indigenous culturally appropriate research protocols, including Indigenous methodologies; and
  4. Promote equity and development of trainees, researchers and knowledge users who are of Indigenous ancestry.

For the Controlled Trial Application to be eligible:

  • For administrative reason, the Nominated Principal Applicants of each Regional Node must be a Principal Applicant on the Controlled Trial Application. One of them should be identified as the Nominated Principal Applicant on the Controlled Trial Application.
  • Participants responsible for directing the Methamphetamine Use Disorder Controlled Trial within each Regional Node must be listed as Principal Applicants (see Regional Node eligibility criterion 4).
  • One Principal Applicant should also be identified as the National Coordinator for the Controlled Trial and be clearly identified as such in the Participant Table (see How to Apply section).
  • For any research involving First Nations, Inuit, Métis and/or Urban Indigenous populations, the research team must include at least one Principal Applicant who self-identifies as Indigenous (First Nations, Inuit or Métis) and/or has a track record of meaningful and culturally safe engagement with Indigenous Peoples. As part of the Controlled Trial Application, a one-page document describing how they meet this requirement must be submitted as an “Other” attachment (see How to Apply section).
How to Apply: 

The specific objective of this funding opportunity are to:

  • provide the base/infrastructure funding to the CRISM Phase II Regional Nodes that will allow research teams to organize and collaborate to address critical research in the area of substance use, and to allow them to:
    • identify and develop clinical and community-based prevention or treatment interventions and guidelines, including harm reduction, for substance use
    • provide evidence to decision makers, providers and stakeholders, to support the enhancement of prevention or treatment services, as well as policy development, regarding substance use
    • engage Indigenous Peoples in Canada in research and KT efforts in a manner respecting the rights of Indigenous Peoples and Indigenous self-determination and self-governance, such as following the First Nations Principles of OCAP® (i.e., Ownership, Control, Access and Possession)1, or employing a distinctions-based approach, (see Additional Information)
    • support the improvement in the quality of care and quality of life for Canadians with substance use disorder
    • involve individuals with lived and living experience throughout the research process 
  • conduct a Controlled Trial for management of methamphetamine use disorder aligned with the NIDA CTN
External Deadline: 
Tuesday, June 15, 2021
Funding Source: 
External
Funding Level: 
Research